Galapagos ships out its CRO biz for $179M to focus on R&D

Damian Garde Belgian biotech Galapagos is getting out of the CRO business, selling off its two contract units to preclinical giant Charles River Laboratories for $ 179 million and ...

High court dashes Actelion’s hopes for $407M reprieve in Tracleer case

Arlene Weintraub Actelion has lost its fight against a $ 407 million court judgment. California's Supreme Court rebuffed the Swiss drugmaker's appeal in a lawsuit over competition ...

Sage snags $38M from A-list VCs to bankroll its seizure drugs

Damian Garde Cambridge, MA's Sage Therapeutics has hauled in a $ 38 million Series C, convincing a who's-who of biotech investors to pitch in as it pushes forward with a portfolio ...

Pfizer’s billion-dollar Celebrex patent loss has Mylan, Actavis revving up generics

Tracy Staton One of Pfizer's top-selling products is suddenly vulnerable to generic competition 18 months earlier than expected. A U.S. court nixed a key Celebrex patent, putting ...

GSK, J&J, TPI want Australia to ease their pain on poppy supplies

Eric Palmer Australia accounts for nearly half of the global supply of opium poppy plants that produce the ingredients needed for pain drugs. But drugmakers are in the midst of a political ...

Geron shares blasted as FDA slams the brakes on imetelstat studies

John Carroll Geron is back in the tank. The biotech's shares were in meltdown mode Wednesday morning, plunging about 60% in premarket trading after the company announced that the ...

In SGLT2 diabetes fight, Lilly’s empagliflozin loss is J&J and AstraZeneca’s gain

Tracy Staton Johnson & Johnson and AstraZeneca will just have to duke it out for share of the market for SGLT2 treatments for diabetes. A potential third competitor from Eli Lilly ...

Novartis’ ‘breakthrough’ muscle drug is worth $4B, if you ask MorphoSys

Damian Garde Novartis is making its way into late-stage studies for the orphan drug bimagrumab, and co-developer MorphoSys said sales of the muscle-growing treatment could peak at $ ...

Aventis spinout Scynexis plots a $55M IPO to push an ex-Merck antibiotic

Damian Garde Durham, NC's Scynexis is queuing up for a $ 55 million IPO, looking to ride the wave of biotech bullishness and raise cash for its in-development anti-infective. FierceBiotech ...

Drugmakers, FDA need a SWAT team approach on shortages, group says

Eric Palmer The FDA has reduced the number of new drug shortages considerably, and hospitals have gotten much better at responding when they occur. But the total number of drug shortages ...

Actelion’s diarrhea drug hops on the FDA fast track

Damian Garde The FDA has granted its fast-track status to Actelion's Phase III drug for C. difficile-related diarrhea, promising a shorter path to approval for the antibiotic treatment. FierceBiotech ...

Amarin lashes out at FDA with lawsuit over Vascepa exclusivity

Eric Palmer Amarin, which has faced a series of setbacks getting its fish oil pill to market, is lashing out at the FDA for some of its problems, Bloomberg reports. FiercePharma News
Page 2 of 212
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS